Studies of viral entry into host cells often rely on the detection of post-entry parameters, such as viral replication or the expression of a reporter gene, rather than on measuring entry per se. The lack of assays to easily detect the different steps of entry severely hampers the analysis of this key process in virus infection. Here we describe novel, highly adaptable viral entry assays making use of minimal complementation of the E. coli β-galactosidase in mammalian cells. Enzyme activity is reconstituted when a small intravirion peptide (α-peptide) is complementing the inactive mutant form ΔM15 of β-galactosidase. The method allows to dissect and to independently detect binding, internalization, and fusion of viruses during host cell entry. Here we use it to confirm and extend current knowledge on the entry process of two enveloped viruses: vesicular stomatitis virus (VSV) and murine hepatitis coronavirus (MHV).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099126 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0101762 | PLOS |
RSC Adv
January 2025
Graduate School of Environmental Symbiotic System Major, Nippon Institute of Technology 4-1 Gakuendai, Miyashiro Saitama 345-8501 Japan.
Coiled-coil protein carrier (CCPC) 140 is a rigid and anisotropically structured cationic coiled-coil artificial protein that has displayed up to a 1000 times higher level of cellular internalization activity than that of unstructured cell-penetrating peptides. Previous studies have demonstrated that CCPC 140's rigid and anisotropic structural properties and cationic surface properties are important for its superior cellular internalization activity. In this study, we investigated whether each physicochemical characteristic of CCPC 140 effectively contributed to activating the cellular internalization pathway.
View Article and Find Full Text PDFJ Immunother Cancer
December 2024
Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA
Background: Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. Fusion proteins and immunoconjugates represent an innovative therapeutic approach to specifically deliver a deadly payload to target cells. Epithelial membrane protein-2 (EMP2) is highly expressed in invasive breast cancer (BC), including triple-negative BC (TNBC), and represents an attractive therapeutic target.
View Article and Find Full Text PDFPsychol Rev
January 2025
Department of Psychological and Brain Sciences, Dartmouth College.
Our premodern ancestors had perceptual, motoric, and cognitive functional domains that were modularly encapsulated. Some of these came to interact through a new type of cross-modular binding in our species. This allowed previously domain-dedicated, encapsulated motoric and sensory operators to operate on operands for which they had not evolved.
View Article and Find Full Text PDFAcc Chem Res
January 2025
Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada.
ConspectusStructural DNA nanotechnology offers a unique self-assembly toolbox to construct soft materials of arbitrary complexity, through bottom-up approaches including DNA origami, brick, wireframe, and tile-based assemblies. This toolbox can be expanded by incorporating interactions orthogonal to DNA base-pairing such as metal coordination, small molecule hydrogen bonding, π-stacking, fluorophilic interactions, or the hydrophobic effect. These interactions allow for hierarchical and long-range organization in DNA supramolecular assemblies through a DNA-minimal approach: the use of fewer unique DNA sequences to make complex structures.
View Article and Find Full Text PDFViruses
December 2024
School of Medicine, Zhejiang University, Hangzhou 310063, China.
The Junín virus (JUNV) is one of the New World arenaviruses that cause severe hemorrhagic fever. Human transferrin receptor 1 (hTfR1) has been identified as the main receptor for JUNV for virus entry into host cells. To date, no treatment has been approved for JUNV.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!